DareBio_Stacked_Fullcolor_RGB.jpg
Daré Bioscience Secures $12 million in Royalty-backed Investment Structure
26 déc. 2023 08h00 HE | Daré Bioscience, Inc.
SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it has entered into a royalty-backed financing agreement...
DareBio_Stacked_Fullcolor_RGB.jpg
Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study
20 déc. 2023 08h00 HE | Daré Bioscience, Inc.
SAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced positive topline results from the Phase 1 study evaluating...
DareBio_Stacked_Fullcolor_RGB.jpg
Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study
13 déc. 2023 08h00 HE | Daré Bioscience, Inc.
DARE-PTB1 is being developed as a treatment to reduce the risk of preterm birth, for which there are no FDA-approved treatment options Up to approximately $2 million in grant funding to support...
DareBio_Stacked_Fullcolor_RGB.jpg
Daré Bioscience Announces FDA Clearance of Investigational New Drug (IND) Application for DARE-VVA1, a Novel Intravaginal Formulation of Tamoxifen for Moderate to Severe Dyspareunia, a Symptom of Vulvar and Vaginal Atrophy Associated with Menopause
07 déc. 2023 08h00 HE | Daré Bioscience, Inc.
SAN DIEGO, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared...
DareBio_Stacked_Fullcolor_RGB.jpg
Daré Bioscience Announces Commencement of Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive
04 déc. 2023 08h00 HE | Daré Bioscience, Inc.
SAN DIEGO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced commencement of the Company’s pivotal Phase 3 clinical study...
DareBio_Stacked_Fullcolor_RGB.jpg
Daré Bioscience and Premier Research Extend Strategic Partnership to Accelerate the Clinical Development of Daré’s Novel Women’s Health Programs
20 nov. 2023 08h00 HE | Daré Bioscience, Inc.
SAN DIEGO and MORRISVILLE, N.C., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and Premier Research International, LLC, a global...
DareBio_Stacked_Fullcolor_RGB.jpg
Daré Bioscience to Present at the Sexual Medicine Society of North America (SMSNA) 24th Annual Fall Scientific Meeting
13 nov. 2023 08h00 HE | Daré Bioscience, Inc.
SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and its collaborator Strategic Science & Technologies, LLC (SST),...
DareBio_Stacked_Fullcolor_RGB.jpg
Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update
09 nov. 2023 08h00 HE | Daré Bioscience, Inc.
Conference Call and Webcast Today at 4:30 p.m. ET What to Expect for the Remainder of 2023 XACIATO™: receipt of $1.8 million triggered by achievement of first commercial milestone under license...
DareBio_Stacked_Fullcolor_RGB.jpg
Daré Bioscience to Participate in Three November Conferences
06 nov. 2023 08h00 HE | Daré Bioscience, Inc.
SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the company’s President and CEO, Sabrina Martucci...
DareBio_Stacked_Fullcolor_RGB.jpg
Daré Bioscience to Host Third Quarter 2023 Financial Results and Company Update Conference Call and Webcast on November 9, 2023
02 nov. 2023 08h00 HE | Daré Bioscience, Inc.
SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30...